<qa>  What is the primary objective of the study?The primary objective of the study is to determine the objective response rate ORR at Day 50 in patients with relapsed or refractory classic systemic anaplastic large cell lymphoma csALCL or primary cutaneous ALCL pcALCL treated with MDX-060. The ORR will be based on an adaption of the NCI Response Criteria for Non-Hodgkins Lymphoma NHL for patients with csALCL and will be based on the Physicians Global Assessment PGA for patient with pcALCL. 